Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.68 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
| ▸ | TOP2A | P11388 | 1/20 | 0.55 |
| ▸ | TAF1 | P21675 | 1/20 | 0.52 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 4/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.52 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.49 |
| ▸ | SALL4 | Q9UJQ4 | 1/20 | 0.49 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16424662 | 0.96 | BRD4 (0.67) | BRD4ADRA1BHDAC4HDAC7HDAC9 | |
| SCHEMBL16424675 | 0.87 | BRD4 (0.70) | BRD4HDAC4HDAC5TAF1TAF1L | |
| SCHEMBL20286076 | 0.86 | BRD4 (0.52) | BRD4ADRA1BHDAC4HDAC7HDAC9 | |
| SCHEMBL16424681 | 0.83 | BRD4 (0.69) | BRD4SALL4 | |
| SCHEMBL16424669 | 0.82 | BRD4 (0.70) | BRD4HDAC4HDAC5TAF1TAF1L | |
| SCHEMBL20286082 | 0.81 | BRD4 (0.67) | BRD4TOP2ATAF1TAF1L | |
| SCHEMBL16424682 | 0.81 | BRD4 (1.00) | BRD4ADRA1BHDAC4HDAC7HDAC9 | |
| SCHEMBL25416714 | 0.81 | ADRA1B (0.91) | BRD4ADRA1BHDAC4HDAC7HDAC9 | |
| SCHEMBL21143289 | 0.80 | BRD4 (0.48) | BRD4HDAC4HDAC7HDAC9HDAC5 | |
| SCHEMBL20889469 | 0.80 | ADRA1B (0.61) | BRD4ADRA1BHDAC4HDAC7HDAC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975896-B2 | Inhibitors of transcription factors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160168154-A1 | INHIBITORS OF TRANSCRIPTION FACTORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168154-A1 | INHIBITORS OF TRANSCRIPTION FACTORS AND USES THEREOF | BRD4, BRPF3, EP300 | BRD4 1/4885ADRA1B 3038/4885HDAC4 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.